Literature DB >> 11004700

Errors in histological grading by prostatic needle biopsy specimens: frequency and predisposing factors.

E Ruijter1, G van Leenders, G Miller, F Debruyne, C van de Kaa.   

Abstract

Sampling error is an inherent problem of prostate biopsy. Consequently, there are problems in determining whether a given carcinoma is clinically significant on the basis of biopsy results. This study assesses the factors that predispose to errors in biopsy grading, as well as the dimensions of sampling error due to these factors. Among 187 cases, biopsy grading error was retrospectively related to grade heterogeneity in the prostate and to biopsy-related factors. Clinically relevant biopsy grading errors occurred in a quarter of the cases. Of all grading errors, at least 17% resulted from misinterpretation by the pathologist only. Overall, prostates with grade heterogeneity revealed grading errors twice as frequently as specimens without grade heterogeneity. In most cases, however, grading error resulted from multiple factors, such as the number and length of cores obtained (p<0.05). This was an important finding because the mean core length was only 9.4 mm, whereas the biopsy needle is designed to obtain cores of 15 mm. Moreover, clinically relevant biopsy grading error had occurred in almost half of the cases when the Gleason score was based on a tumour deposit measvring less than 0.5 mm (p<0.05). The clinical consequences of these findings are important. Clinicians should try to obtain at least six biopsies, each 15 mm in length, to minimize grading error. Pathologists should be cautious in reporting Gleason scores based on tumour lesions smaller than 400x total magnification field. Interpretation could be refined, when necessary, by warning the urologist of the Limitations of the biopsy report. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 11004700     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH703>3.0.CO;2-X

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

1.  Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer.

Authors:  Stephanie Thomas; Peter Waterman; Suelin Chen; Brett Marinelli; Marc Seaman; Scott Rodig; Robert W Ross; Lee Josephson; Ralph Weissleder; Kimberly A Kelly
Journal:  J Nanomed Nanotechnol       Date:  2011-08

2.  The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.

Authors:  Al B Barqawi; Ruslan Turcanu; Eduard J Gamito; Scott M Lucia; Colin I O'Donnell; E David Crawford; David D La Rosa; Francisco G La Rosa
Journal:  Int J Clin Exp Pathol       Date:  2011-06-12

Review 3.  Histopathological image analysis: a review.

Authors:  Metin N Gurcan; Laura E Boucheron; Ali Can; Anant Madabhushi; Nasir M Rajpoot; B Yener
Journal:  IEEE Rev Biomed Eng       Date:  2009-10-30

4.  Temporal changes in the pathologic assessment of prostate cancer.

Authors:  M Scott Lucia; Adrie van Bokhoven
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

Review 5.  Correlation between Gleason Scores in Needle Biopsy and Corresponding Radical Prostatectomy Specimens: A Twelve-Year Review.

Authors:  Maliheh Khoddami; Yassaman Khademi; Maryam Kazemi Aghdam; Haleh Soltanghoraee
Journal:  Iran J Pathol       Date:  2016

6.  Is quadrant biopsy sufficient in men likely to have advanced prostate cancer? Comparison with extended biopsy.

Authors:  Zoran Brnic; Slavko Gasparov; Petar Vladislav Lozo; Petar Anic; Leonardo Patrlj; Vesna Ramljak
Journal:  Pathol Oncol Res       Date:  2005-03-31       Impact factor: 3.201

7.  Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy.

Authors:  Carolina D'Elia; Maria Angela Cerruto; Antonio Cioffi; Giovanni Novella; Stefano Cavalleri; Walter Artibani
Journal:  Mol Clin Oncol       Date:  2014-08-05

8.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.

Authors:  Jonathan I Epstein; Zhaoyong Feng; Bruce J Trock; Phillip M Pierorazio
Journal:  Eur Urol       Date:  2012-02-08       Impact factor: 20.096

9.  Factors predicting pathological upgrading after prostatectomy in patients with Gleason grade group 1 prostate cancer based on opinion-matched biopsy specimens.

Authors:  Yuki Maruyama; Takuya Sadahira; Motoo Araki; Yosuke Mitsui; Koichiro Wada; Acosta Gonzalez Herik Rodrigo; Kazuaki Munetomo; Yasuyuki Kobayashi; Masami Watanabe; Hiroyuki Yanai; Toyohiko Watanabe; Yasutomo Nasu
Journal:  Mol Clin Oncol       Date:  2020-02-10

Review 10.  Harnessing non-destructive 3D pathology.

Authors:  Jonathan T C Liu; Adam K Glaser; Kaustav Bera; Lawrence D True; Nicholas P Reder; Kevin W Eliceiri; Anant Madabhushi
Journal:  Nat Biomed Eng       Date:  2021-02-15       Impact factor: 25.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.